ACC2-IN-1 

ACC2-IN-1 is an orally active, selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), with an IC₅₀ of 1.9 nM against human targets. ACC2-IN-1 acts as a reducing agent to decrease malonyl-CoA levels in skeletal muscle and exhibits a favorable CYP450 inhibition profile. ACC2-IN-1 can be used in the research of type 2 diabetes^[1].

ACC2-IN-1 (compound 2e) potently inhibits human ACC2 with an IC₅₀ of 1.9 nM and is 1026-fold selective over human ACC1^[1].
ACC2-IN-1 (30 min) exhibits high metabolic stability, with 91% and 100% remaining after incubation in human and rat liver microsomes, respectively^[1].
ACC2-IN-1 has an acceptable CYP450 inhibition profile, with no inhibition of CYP1A2, CYP2D6, or CYP3A4 at concentrations up to 20 μM, and IC₅₀ values of 18 μM for CYP2C19 and 13 μM for CYP2C9^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ACC2-IN-1 (compound 2e) (1.0-2.5 mg/kg; p.o.; single dose) produces dose-dependent reductions in skeletal muscle malonyl-CoA levels in C57BL/6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

417.91

C₂₀H₂₀ClN₃O₃S

2237229-78-4

ClC1=C2C(N=C(S2)OCC)=CC=C1OC3=CC=C(C=N3)/C=C/[C@H](C)NC(C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Nishiura Y, et al. Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy. Bioorg Med Chem Lett. 2018;28(14):2498-2503.  [Content Brief]